More from that Forbes article:
Norway
'In March, for example, the Norwegian Healthcare Investigation Board announced it would revise its current clinical recommendations. The updated guidelines restrict the use of puberty blockers, cross-sex hormones and transition-related surgery to clinical research settings.'
UK
''The British National Health Service announced last year an interim policy which maintains that “puberty-suppressing hormones should not be routinely commissioned for children and adolescents” outside of research settings, citing the “significant uncertainties” surrounding the use of hormone treatments..'
Sweden
'A 2022 report commissioned by the Swedish government concluded that the “scientific basis is not sufficient” to continue to conduct hormone treatments on children without further research. Health officials stated that puberty blockers, hormones, and mastectomies should only be used in “exceptional cases,” as the risks are likely to outweigh benefits.'
Denmark
'A marked shift in policy this year has meant that in Denmark most youth referred to the centralized gender clinic no longer get a prescription for puberty blockers, hormones or surgery. Rather, they receive therapeutic counseling and other support services.'
France
'In France, the Académie Nationale de Médecine in February 2022 recommended the “greatest reserve” when considering puberty blockers or hormone treatments. The academy warned that the risk of “over-diagnosis” is real and urged caution when evaluating patients.'
Finland
'After years of additional research, a public health body in Finland recommended that minors experiencing gender dysphoria first be provided with psychological support and, if further medical treatment is pursued, that the patient be made “aware of the risks associated with them.”
Ultimately, this gave rise to Finnish health authorities conducting systematic reviews of evidence for the benefits and risks of hormonal interventions. Subsequently, the findings from these reviews suggested that studies cited in support of hormonal interventions for adolescents are of “very low” certainty. In turn, this led to the placement of severe restrictions on access to hormones.'
Netherlands
'Even in the Netherlands, where practice guidelines haven’t been revised yet, in an article published in February of this year the author concluded that “more research on sex changes in young people under the age of 18 is urgently needed,” in particular, referring to the importance of examining the long-term effects of “medicalized” transgender care.'